Overview

A Phase 2/3 Study in Adult and Pediatric Participants With Sickle Cell Disease (SCD)

Status:
Not yet recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GBT021601.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Global Blood Therapeutics